STAT3 activation in glioblastoma: Biochemical and therapeutic implications

Jennifer E. Kim, Mira Patel, Jacob Ruzevick, Christopher M. Jackson, Michael Lim

Research output: Contribution to journalReview article

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a potent regulator of gliomagenesis through its induction of angiogenesis, host immunosuppression, and tumor invasion. Gain of function mutations result in constitutive activation of STAT3 in glioma cells, making STAT3 an attractive target for inhibition in cancer therapy. Nevertheless, some studies show that STAT3 also participates in terminal differentiation and apoptosis of various cell lines and in glioma with phosphatase and tensin homolog (PTEN)-deficient genetic backgrounds. In light of these findings, the utility of STAT3 as a prognostic indicator and as a target of drug therapies will be contingent on a more nuanced understanding of its pro-and anti-tumorigenic effects.

Original languageEnglish (US)
Pages (from-to)376-395
Number of pages20
JournalCancers
Volume6
Issue number1
DOIs
StatePublished - Mar 1 2014

    Fingerprint

Keywords

  • Glioblastoma
  • Immunotherapy
  • STAT3

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this